Table 1. Pretreatment Clinical and... | American Society of Hematology

Table 1.

Pretreatment Clinical and Hematologic Findings and Responses to 4 Months of Therapy in Patients Randomized to Oral Cyanocobalamin

Patient No.	Age/Sex	Diagnosis^*	Therapy	Hematocrit (%)		MCV (fL)		Neurologic Symptoms^-152
Patient No.	Age/Sex	Diagnosis^*	Therapy	Pre^-151	4 mo^-151	Pre	4 mo	Pre	4 mo
1	70/F	AG	Oral	35	40	107	91
2	76/F	PA, Diet	Oral	20	41	129	80	Memory loss	Improved
3	43/F	PA	Oral	25	38	118	83
4	69/M	AG	Oral	41	40	90	89	Paresthesias	Improved
5	67/M	PA	Oral	34	43	107	79
6	71/M	PA	Oral	36	41	87	81
7	71/F	AG	Oral	41	39	99	99
8	80/F	AG	Oral	42	42	89	90
9	62/F	AG	Oral	41	41	112	88
10	72/F	?AG, OMEP	Oral	40	40	82	81
11	61/M	Diet	Oral	38	38	101	100
12	81/F	PA	Oral	41	44	102	92
13	84/F	AG	Oral	41	39	97	91	Paresthesias	Cleared
14	92/M	AG	Oral	43	46	100	100
15	68/F	IR	Oral	42	40	92	91
16	80/F	?AG	Oral	42	42	94	95	Paresthesias, ataxia	Cleared
17	75/F	Diet	Oral	35	36	87	81
18	77/M	?AG, HIST	Oral	39	39	95	96
Mean ± SD	72 ± 11		Oral	37.6 ± 6.2	40.5 ± 2.9	100 ± 12	90 ± 7

Patient No.	Age/Sex	Diagnosis^*	Therapy	Hematocrit (%)		MCV (fL)		Neurologic Symptoms^-152
Patient No.	Age/Sex	Diagnosis^*	Therapy	Pre^-151	4 mo^-151	Pre	4 mo	Pre	4 mo
1	70/F	AG	Oral	35	40	107	91
2	76/F	PA, Diet	Oral	20	41	129	80	Memory loss	Improved
3	43/F	PA	Oral	25	38	118	83
4	69/M	AG	Oral	41	40	90	89	Paresthesias	Improved
5	67/M	PA	Oral	34	43	107	79
6	71/M	PA	Oral	36	41	87	81
7	71/F	AG	Oral	41	39	99	99
8	80/F	AG	Oral	42	42	89	90
9	62/F	AG	Oral	41	41	112	88
10	72/F	?AG, OMEP	Oral	40	40	82	81
11	61/M	Diet	Oral	38	38	101	100
12	81/F	PA	Oral	41	44	102	92
13	84/F	AG	Oral	41	39	97	91	Paresthesias	Cleared
14	92/M	AG	Oral	43	46	100	100
15	68/F	IR	Oral	42	40	92	91
16	80/F	?AG	Oral	42	42	94	95	Paresthesias, ataxia	Cleared
17	75/F	Diet	Oral	35	36	87	81
18	77/M	?AG, HIST	Oral	39	39	95	96
Mean ± SD	72 ± 11		Oral	37.6 ± 6.2	40.5 ± 2.9	100 ± 12	90 ± 7

*AG indicates evidence of chronic atrophic gastritis (low serum pepsinogen [<30 μg/L] in each instance with elevated serum gastrin [>100 pmol/L] in all except no. 8). In a series of 120 consecutive patients (J. Lindenbaum, unpublished data) with proven pernicious anemia (defined as the presence of antibodies to intrinsic factor and unequivocal evidence of cobalamin deficiency), serum pepsinogen concentrations were less than 30 μg/L in 110 (90.9%), in contrast to 2.5% of 120 normal controls. In the remaining 10 patients with pernicious anemia, serum pepsinogen levels varied from 30 to 70 μg/L, in the lower half of the normal range. Serum gastrin levels were greater than 100 pmol/L in 105 (87.5%) of the 120 patients with pernicious anemia, in contrast to none of the controls. PA indicates pernicious anemia (serum antibodies to intrinsic factor and low pepsinogen in each instance, with elevated serum gastrin in all except no. 6); ?AG indicates serum pepsinogen 47 to 67 μg/L, with elevated serum gastrin only in no. 18. OMEP indicates chronic omeprazole therapy for esophageal reflux; HIST indicates chronic H₂-blocker therapy. Diet indicates inadequate dietary protein intake. IR indicates prior ileal resection.

F0-151

Pre indicates pretreatment value; 4 mo indicates value after 4 months of oral cyanocobalamin at 2,000 μg/d.

F0-152

Improved indicates dramatic improvement in neurologic symptoms and cleared indicates complete resolution of symptoms at 4 months.

View Large

This Feature Is Available To Subscribers Only